根据名称进行药物检索

Dilantin-125 与 Divalproex Sprinkle

Dilantin-125 与 Divalproex Sprinkle互相作用以及同时服用的可能性。

检测结果:

Dilantin-125 <> Divalproex Sprinkle

现实性: 01.09.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

之前把苯妥英告诉你的医生，如果你还利用双丙戊酸钠。你可能需要的剂量调整或特别的测试，以便安全地把这两种药物在一起。你应该通知你的医生如果你有症状，例如昏昏欲睡、视觉问题，行为变化、恶心或贫穷的肌肉的协调。重要的是，你告诉你的医疗保健提供者有关的所有其他药物的使用，包括维生素和草药。不停止使用药物而不首先说你的医生第一次。

医界专家:

监视器：丙戊酸(和其衍生物)可以增加药理作用的苯妥英。毒性结果，尽管常苯妥英的水平。该机制可将有关流离失所问题的苯妥英从血浆中的蛋白质。此外，苯妥英会引起的CYP450新陈代谢的丙戊酸。类似的相互作用可能发生与其他脲.

管理：患者治疗的组合应密切监测临床和实验室证据的改变苯妥英和丙戊酸钠的影响。它可能更有用的监测等离子体自由苯妥英水平比以监测总的等离子浓度。患者应建议通知他们的医生如果他们经历的症状的毒性(例如昏昏欲睡、视觉障碍，改变，在精神状态、缉获、恶心或共济失调)。

来源

Bourgeois BF "Pharmacologic interactions between valproate and other drugs." Am J Med 84 (1988): 29-33
Perucca E, Hebdige S, Frigo GM, et al "Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects." Clin Pharmacol Ther 28 (1980): 779-89
Riva R, Albani F, Contin M, Baruzzi A "Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations." Clin Pharmacokinet 31 (1996): 470-93
May T, Rambeck B "Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication." Ther Drug Monit 12 (1990): 124-8
Lai ML, Huang JD "Dual effect of valproic acid on the pharmacokinetics of phenytoin." Biopharm Drug Dispos 14 (1993): 365-70
Bruni J, Gallo JM, Lee CS, et al "Interactions of valproic acid with phenytoin." Neurology 30 (1980): 1233-6
Riva R, Albani F, Contin M, Perucca E, Ambrosetto G, Gobbi G "Time-dependent interaction between phenytoin and valproic acid." Neurology 35 (1985): 510-5
Palm R, Silseth C, Alvan G "Phenytoin intoxication as the first symptom of fatal liver damage induced by sodium valproate." Br J Clin Pharmacol 17 (1984): 597-9
Pospisil J, Perlik F "Binding parameters of phenytoin during monotherapy and polytherapy." Int J Clin Pharmacol Ther Toxicol 30 (1992): 24-8
Sallustio BC, Morris RG "Unbound plasma phenytoin concentrations measured using enzyme immunoassay technique on the cobas MIRA analyser: in vivo effect of valproic acid." Ther Drug Monit 14 (1992): 9-13
Rodin EA, DeSoussa G, Haidukewych D, et al "Dissociation between free and bound phenytoin levels in presence of valproate sodium." Arch Neurol 38 (1981): 240-2
Henriksen O, Johannessen SI "Clinical and pharmacokinetic observations on sodium valproate: a 5-year follow-up study in 100 children with epilepsy." Acta Neurol Scand 65 (1982): 504-23
Kerrick JM, Wolff DL, Graves NM "Predicting unbound phenytoin concentrations in patients comedicated with valproate." Epilepsia 34 Suppl (1993): 112
Sackellares JC, Sato S, Dreifuss FE, Penry JK "Reduction of steady-state valproate levels by other antiepileptic drugs." Epilepsia 22 (1981): 437-41
Suzuki Y, Nagai T, Mano T, Arai H, Kodaka R, Matsuoka T, Itagaki Y, Ono J, Okada S "Interaction between valproate formulation and phenytoin concentrations." Eur J Clin Pharmacol 48 (1995): 61-3